Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations

This study is testing new, targeted medications for people with meningiomas—a type of brain lining tumor—that are continuing to grow or have come back after treatment. The goal is to see if these drugs can block the specific signals that tell these tumor cells to multiply, potentially stopping or slowing the disease.

This trial is for patients who have been diagnosed with a progressive meningioma that shows specific genetic changes in their tumor cells. Doctors will test your tumor tissue to see if these specific targeted therapies are a good match for your unique situation.

Participants will receive one of the study medications, which are designed to stop tumor growth by blocking the signals the cells need to survive. Throughout the trial, your healthcare team will closely monitor your health and how your tumor responds to the treatment.

The study is currently recruiting new participants and is taking place at locations in Birmingham, Alabama, and Anchorage, Alaska. You can talk to your doctor to see if one of these locations is accessible for your care.